Comparison of the pharmacokmetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers

European Journal of Clinical Pharmacology

Volumn 60, Issue 4, 2004, Pages 247-253

  Sobue, Satoshi ^a   Tan, Keith ^b   Shaw, Linda ^b   Layton, Gary ^b   Hust, Rita ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c FOCUS Clinical Drug Development GmbH   (Germany)

Author keywords

Fosfluconazole; Pharmacokinetics; Racial difference

Indexed keywords

FLUCONAZOLE; FOSFLUCONAZOLE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; DRUG DERIVATIVE; ORGANOPHOSPHATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BOLUS INJECTION; CAUCASIAN; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG TOLERABILITY; DRUG URINE LEVEL; ECG ABNORMALITY; ETHNIC GROUP; FEMALE; HEADACHE; HEMOCONCENTRATION; HEMOGLOBINURIA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TIME; URINALYSIS; ASIAN; BIOAVAILABILITY; ETHNOLOGY; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; METABOLIC CLEARANCE RATE; MIDDLE AGED;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUCONAZOLE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHOSPHORIC ACID ESTERS;

EID: 3142694895     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Marriot MS, Richardson K (1987) The discovery and mode of action of fluconazole. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous Science Publishers, SA, Barcelona, pp 81-92
2. Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ (1990) Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 12:8267-8271
3. Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79
4. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662-678
5. Goa KL, Barradell LB (1995) Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50:658-690
6. Troke PF (1997) Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. Eur J Clin Microbiol Infect Dis 16:287-295
7. Bentley A, Butters M, Green SP, Learmonth WJ, Macrae JA, Morland MC, O'Connor G, Skuse J (2002) The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org Process Res Dev 6:109-112
8. Sobue S, Sekiguchi K, Shimatani K, Tan K (2004) Pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers. J Clin Pharmacol 44:284-292
9. Shiba K, Saito A, Miyahara T (1990) Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects. Clin Ther 12:206-215
10. Brammer KW, Farrow PR, Faulkner JK (1990) Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12:S318-S326
11. Humphrey MJ, Jevons S, Tarbit MH (1985) Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 28:648-653
12. Orimo H, Goseki-Sone M, Inoue M, Tsubakio Y, Sakiyama T, Shimada T (2002) Importance of deletion of T at nucleotide 1559 in the tissue-nonspecific alkaline phosphatase gene in Japanese patients with hypophosphatasia. J Bone Miner Metab 20:28-33
13. Wennberg C, Sikstrom C (1995) DNA polymorphisms and haplotypes of human liver/bone/kidney alkaline phosphatase in Finns, Saamis and Swedes. Hum Hered 45:61-64
14. Herasse M, Spentchian M, Taillandier A, Mornet E (2002) Evidence of a founder effect for the tissue-nonspecific alkaline phosphatase (TNSALP) gene E174 K mutation in hypophosphatasia patients. Eur J Hum Genet 10:666-668
15. Mornet E (2000) Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene. Hum Mutat 15:309-315
16. Mumm S, Jones J, Finnegan P, Henthorn PS, Podgornik MN, Whyte MP (2002) Denaturing gradient gel electrophoresis analysis of the tissue nonspecific alkaline phosphatase isoenzyme gene in hypophosphatasia. Mol Genet Metab 75:143-153
17. Henthorn PS, Raducha M, Fedde KN, Lafferty MA, Whyte MP (1992) Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia. Proc Natl Acad Sci U S A 89:9924-9928
18. SAS Institute Inc (1994) SAS/SAT Users Guide, version 6.09, 4th edn. SAS Institute Inc., Cary, NC
19. Fernley HN (1971) Mammalian alkaline phosphatases. In: Boyer PD (ed) The enzymes, 3rd edn. Academic Press, New York, pp 417-447
20. Nouwen EJ, De Broe ME (1994) Human intestinal versus tissue-nonspecific alkaline phosphatase as complementary urinary markers for the proximal tubule. Kidney Int 46[Suppl 47]:S43-S51
21. Guder WG, Ross BD (1984) Enzyme distribution along the nephron. Kidney Int 26:101-111
22. Sobue S, Tan K, Layton G, Leclerc V, Weil A (2004) The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br J Clin Pharmacol (in press)